BioTissue begins skin substitute study:
This article was originally published in Clinica
German tissue engineering firm BioTissue Technologies has begun an international, multicentre study of its skin cell substitute, BioSeed-S, designed to generate data to support the coverage of the product by health insurance bodies. Professor Wolfgang Vanscheidt, director of the Wound Biology Clinic in Hochenschwand, Germany, and president of the German Wound Healing Association, is heading the study. BioSeed-S is already being marketed globally under an exclusive marketing deal between Freiburg-based BioTissue Technologies and Baxter International.
You may also be interested in...
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.
The European Court of Justice rules that CBD cannot be regarded as a narcotic as it is non-psychoactive and suggests that a French ban on the cannabinoid is contrary to EU law on the free movement of goods. Legal experts and industry hope the judgment will pave the way for a regulated European CBD market.